High-value medical consumables once again ushered in the national-level volume procurement.

on September 14, the joint procurement office of high-value medical consumables organized by the state announced the "announcement on centralized procurement of medical consumables for intraocular crystals and sports medicine organized by the state (no 1)" and an enterprise training meeting will be held on September 19, which means that the fourth batch of high-value medical consumables, which has been laid the foundation for a long time, will be officially launched.

2020, the first high-value medical supplies country to target coronary stents, since then orthopaedic artificial joints and orthopaedic spine supplies have been included in the country, the decline is obvious, the high-value consumables collection includes ophthalmology artificial crystals and orthopaedic sports medicine.

In fact, artificial crystals or sports medicine products have previously experienced local or multi-provincial alliance collection, the industry has a certain expectation. Like high-value consumables such as artificial joints, the above two types of products were previously imported in China. The industry generally believes that centralized procurement is conducive to accelerating domestic substitution of imports.

on September 15, the surging news reporter contacted a number of A- share listed companies as investors. Some enterprises said that they would participate in the centralized purchase. The impact on the company depends on the selected price and volume.

The procurement cycle is two years, divided into AB two bidding units

The last collection of high-value consumables was the collection of high-value medical consumables for orthopedics organized by the State in September 2022, which included five kinds of orthopedics consumables for the spine, with a final average decrease of 84%. For the new batch of high-value consumables, Shi Zihai, deputy director of the State Medical Security Administration, once "spoiled" at the series of theme press conferences of the State Information Office on May 18 this year: at the national level, the eighth batch of drug collection has been carried out this year, and the fourth batch of high-value medical consumables will also be collected, mainly for ophthalmology intraocular lenses and orthopaedic sports medicine consumables.

as can be seen from the newly released document no 1, the intraocular lens collected this time covers 2 consumable varieties of intraocular lens (including pusher) and viscoelastic agent, totaling 11 product categories, while sports medicine includes 7 consumable varieties of consumable varieties, such as thread anchor and suture for repair, totaling 20 product categories. The purchase cycle of this centralized purchase is 2 years, starting from the actual execution date of the selected result.

according to the requirements of the document, public medical institutions using artificial crystal or sports medicine medical consumables in the alliance area shall participate. Medical insurance designated social medical institutions and social medical institutions will voluntarily participate in accordance with the relevant regulations of the province (region, city) under the premise of promising to abide by the centralized procurement regulations. In terms of procurement volume, the Joint Procurement Office organizes enterprises to maintain product information, organizes medical institutions to fill in the procurement demand, and summarizes the procurement demand to form a certain proportion of the intended procurement volume.

in terms of bidding, this centralized purchase is still divided into groups a and B, I .e. enterprises that can supply all regions of the country. according to the demand of medical institutions from more to less, enterprises covered by the top 85% of the cumulative demand of this product category are selected to enter bidding unit a; Enterprises that can supply all regions of the country but have not entered bidding unit a, or can not meet the supply of enterprises in all regions of the country to enter the B bidding unit. The declared price of the enterprise includes the price of the product, the cost of distribution and supporting tools and accompanying services, and the declared price of the artificial crystal must include the cost of the pusher.

The selection rules are divided into two. The first is that in the and B bidding units, the shortlisted enterprises are determined according to the ranking of the bidding price of the effective declared enterprises from low to high. The second is to adopt appropriate methods to promote the selection of more enterprises and enhance the expected stability on the premise of ensuring fair competition, maintaining the intensity of competition and eliminating the space for inflated prices, without being limited by the number of enterprises shortlisted in Rule I.

in terms of component rules, according to the requirement of linking quantity and price, the selected products are ranked from low to high according to the quotation, and the basic quantity is allocated according to the gradient of ranking. The intended purchase volume of unallocated and non-selected products is taken as the residual quantity, and when the residual quantity is allocated, on the basis of the independent choice of medical institutions, the enterprises with the highest order of selection shall be tilted, and the enterprises with the lowest order of selection shall be appropriately restricted. For the collection of rules, Guotai Junan believes that the rules as a whole in line with expectations, the rules are still to be clarified.

A number of companies say they will participate in the collection of intraocular lenses and sports medicine. What is the impact?

An intraocular lens is an intraocular lens made of a polymer material that can be implanted in the eye. It usually consists of a circular optic and a peripheral support haptic to replace the natural lens that is removed during cataract surgery. Regarding the impact of the artificial crystal national procurement on the company, surging news reporters contacted Aibo Medical (688050) and Haohai Biotech (688366.SH), but did not receive a direct response. However, artificial crystals have previously entered the regional collection, and the two companies mentioned the impact in their annual reports.

Aibo Medical pointed out in its 2022 annual report that with the gradual expansion of the scope of intraocular lens collection, sales of domestic products have accelerated growth, both in terms of the types of products involved and the geographical areas covered, promoting the localization of imported intraocular lens devices. Domestic IOL manufacturers are actively developing and commercializing high-end IOL products such as multifocal,. trifocal, and EDoF products. With the large-scale implementation of centralized procurement, sales of these new products produced by domestic manufacturers are expected to increase. Therefore, it is expected that the market share of domestic products will increase significantly, especially high-end intraocular lenses, which will further affect the market share of foreign manufacturers in China.

Aibo Medical also stated that with the implementation of centralized procurement, the company's intraocular lens is more popular in the Chinese eye surgery market than imported intraocular lenses, and it is expected to maintain rapid growth in the short term. The company's existing distribution channels and rich hospital-side resources based on collection have laid a solid foundation for the commercialization of new functional artificial lens and lens artificial lens products to be launched.

haohai biotech said in its 2022 annual report that during the reporting period, the procurement of high-value consumables for intraocular lenses in various provinces, cities and alliances entered the second round of procurement cycle one after another. Among them, the second round of volume procurement of the most representative Beijing-Tianjin-Hebei 3+11 alliance and the western nine-province alliance will be completed in December 2021 and March 2022 respectively, and all member provinces in the alliance have entered the next round of procurement cycle one after another during the year. The Group continued to select a number of models of products, covering ordinary and functional spherical intraocular lenses, aspheric intraocular lenses, pre-installed aspheric intraocular lenses, and regional refractive bifocal intraocular lens products, and compared to the first round of volume procurement, the Group's winning products have maintained a stable price system.

Haohai Shengke believes that in the long run, volume procurement will bring more opportunities to enterprises with production cost control and product line layout capabilities. The Group will take advantage of the advantages of multi-brand full product lines, channels and costs to consolidate and further increase the market share of intraocular lens products in the relevant selected regions.

sports medicine belongs to the category of orthopedic implantable medical devices. it mainly treats the soft tissue parts connected between bone and bone, including achilles tendon, ligament, tendon and other tissues. the products behind it include interface nails, anchors, auxiliary systems, power systems, soft tissue reconstruction products and so on. each category includes many small products, for example, auxiliary systems include sutures, portal nails, locking tape loop titanium plates, PEEK ligament fixation sheaths, etc.

chunli medical (688236.SH) 2023 semi-annual report points out that in the field of sports medicine, the company has obtained seven sports medicine registration certificates of PEEK material with thread anchor, disposable cutting head, interface screw, non-absorbable with thread anchor, non-absorbable surgical suture, titanium plate with loop and portal nail, further enriching the company's sports medicine product line and marking the basic completion of the company's layout in the field of sports medicine.

on September 15, surging news reporter contacted chunli medical as an investor. the staff of the other party said that they would participate in the centralized purchase. as for the impact of the centralized purchase price reduction on the company's performance, "it depends on how much the volume is. although the price is reduced, what balance can the volume-price ratio achieve? this depends on how much the reported volume can report."

sports medicine implant consumables source: dabo medical 2023 semi-annual report

Dabo Medical (002901.SZ) has previously participated in the collection of other orthopedic consumables, and has a variety of sports medicine products. As for the impact of centralized procurement, the company mentioned in its 2023 semi-annual report that, driven by the centralized procurement policy, the company won the bid through centralized procurement to further enhance the market share of each orthopedic segment. During the reporting period, the company took advantage of the opportunity of centralized procurement to increase the coverage of medical institutions and drive the growth of product sales by obtaining more surgical volume; affected by the price reduction of centralized procurement, the gross profit of the company's main products declined, which had a certain impact on the company's short-term revenue and profit. In the general environment of comprehensive collection of orthopaedics, the company adheres to innovative research and development as the core driving force, increases investment in research and development, accelerates industrial innovation and upgrading, based on orthopaedics, and continues to promote the common development of multi-product lines in the field of high-value consumables.

sanyou medical (688085.SH) also has sports medicine products. the company mentioned in its semi-annual report that in June 2023, Beijing municipal medical insurance bureau issued "Beijing medical institutions DRG payment and volume procurement linkage management plan (no 1)" and "Beijing medical institutions DRG payment and volume procurement linkage management plan (no 2)". For sports medicine and other medical supplies to develop a DRG payment and volume procurement linkage management program, the company's titanium alloy anchor products participated in this collection.

on September 15, the staff of sanyou medical securities department said that the company had two registration certificates for sports medicine, one of which had previously participated in the above-mentioned collection of sports medicine in Beijing, and the national collection should also participate in this collection. however, it is necessary to see whether the products reported can be included in the list and the selected price before judging the subsequent impact on the company.

A research report by Guosen Securities in July 2023 pointed out that the sports medicine market is different from traditional orthopedics. It is in a stage of rapid growth, and the domestic sports medicine diagnosis and treatment system and capabilities have yet to be improved. With the advancement and cross-application of technology, the field of sports medicine has more room for development and is expected to enter the vast blue ocean of sports rehabilitation. The global sports medicine market has exceeded $6 billion. China 2020The market size has reached 2.7 billion yuan, the annual compound growth rate of 17.6, import manufacturers occupy China's 80% to 90% of the market share, domestic leading accelerated layout, the background of collection is expected to accelerate import substitution.